Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 19, 2017
What are the generic drug sources for oxybutynin and what is the scope of oxybutynin freedom to operate?
Oxybutynin is the generic ingredient in eight branded drugs marketed by Allergan Sales Llc, Barr Labs Div Teva, Mylan, Osmotica Pharm Us, Amneal Pharms, Ortho Mcneil Janssen, Silarx, Unique Pharm Labs, Upsher-smith Labs, Zydus Pharms Usa Inc, Pharm Assoc, Accord Hlthcare, Mikart, Mylan Pharms Inc, Impax Pharms, Usl Pharma, Teva Pharms Usa, Wockhardt, Janssen Pharms, Vintage Pharms, Watson Labs, Quantum Pharmics, and Apotex Inc, and is included in twenty-eight NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.| US Patents: | 11 |
| Tradenames: | 8 |
| Applicants: | 23 |
| NDAs: | 28 |
| Drug Master File Entries: see list | 16 |
| Suppliers / Packagers: see list | 2 |
| Bulk Api Vendors: see list | 51 |
| Clinical Trials: see list | 73 |
| Patent Applications: see list | 5,102 |
| Therapeutic Class: | Genitourinary Agents |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | oxybutynin at DailyMed |
| Drug Class | Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan Sales Llc | OXYTROL | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 021351-002 | Feb 26, 2003 | ► Subscribe | ► Subscribe | ||||||||
Allergan Sales Llc | OXYTROL | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 021351-002 | Feb 26, 2003 | ► Subscribe | ► Subscribe | ||||||||
Allergan Sales Llc | OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211-001 | Jan 25, 2013 | ► Subscribe | ► Subscribe | ||||||||
Allergan Sales Llc | OXYTROL | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 021351-002 | Feb 26, 2003 | ► Subscribe | ► Subscribe | ||||||||
Allergan Sales Llc | OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211-001 | Jan 25, 2013 | ► Subscribe | ► Subscribe | ||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,980,309 | Transdermal testosterone formulation for minimizing skin residues | ► Subscribe | |||||||||||||
| 8,652,491 | Transdermal compositions for anticholinergic agents | ► Subscribe | |||||||||||||
| 7,404,965 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ► Subscribe | |||||||||||||
| 7,087,241 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | ► Subscribe | |||||||||||||
| 7,470,433 | Formulations for transdermal or transmucosal application | ► Subscribe | |||||||||||||
| 8,980,290 | Transdermal compositions for anticholinergic agents | ► Subscribe | |||||||||||||
| 7,387,788 | Pharmaceutical compositions of nicotine and methods of use thereof | ► Subscribe | |||||||||||||
| 7,335,379 | Transdermal pharmaceutical formulation for minimizing skin residues | ► Subscribe | |||||||||||||
| 7,214,381 | Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 1307232 | ► Subscribe | |||||||||||||
| China | 105853396 | ► Subscribe | |||||||||||||
| China | 101305994 | ► Subscribe | |||||||||||||
| Canada | 2718277 | ► Subscribe | |||||||||||||
| Germany | 60127277 | ► Subscribe | |||||||||||||
| Cyprus | 1111498 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2004080413 | ► Subscribe | |||||||||||||
| Australia | 2003287377 | ► Subscribe | |||||||||||||
| Japan | 2017008085 | ► Subscribe | |||||||||||||
| Australia | 2012216593 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,949 others who get our Drug Patent Expiration Alerts:
